Navigation Links
Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Date:4/27/2009

d clinical development positions for Novartis Pharma. Dr. Scaife began his career as the Regulatory and Medical Affairs Manager at Johnson & Johnson Medical Ltd., UK.

Dr. Scaife received a Ph.D. in Toxicology from Leicester School of Pharmacy, United Kingdom and a B.S. degree in Pharmacology from the University of Bath, United Kingdom.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the enrollment, timing and completion of clinical trials of Contrave, and the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
2. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
8. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
9. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
10. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
11. United Therapeutics to Announce 2009 First Quarter Financial Results Before Market Open on Friday, May 1, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... BOSTON , Aug. 27, 2014 Rhythm, ... diseases and genetic deficiencies that result in metabolic disorders, ... on Form S-1 with the U.S. Securities and Exchange ... of shares of its common stock. The number of ... the offering have not yet been determined. ...
(Date:8/27/2014)... In 2013, Lawrence Livermore National ... Security LLC (LLNS), was awarded more than ... laser system for the European Union's Extreme Light ... the Czech Republic. , When commissioned to its ... " High repetition-rate Advanced Petawatt Laser System " ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces ... available in its catalogue: Global ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About ... that are readily decomposed by the action ... non-degradable packaging in terms of raw materials, ...
(Date:8/27/2014)... 2014   MSC , a healthcare performance improvement ... the appointment of Mary Beth Loesch to ... of experience preparing companies for rapid growth and market ... President of Corporate Development and Healthcare. In that role, ... as well as corporate strategy and marketing. Previously, Loesch ...
Breaking Biology Technology:Rhythm Files Registration Statement for Proposed Initial Public Offering 2LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7MSC names Mary Beth Loesch President and CEO 2
... 1 UOP LLC, a Honeywell (NYSE: ... selected for use in Rentech, Inc.,s Rialto Renewable Energy ... The renewable energy center, to be built ... and tree trimmings, into renewable, ultra-clean diesel fuel and ...
... DGP Group, Intelsius, a global manufacturer and distributor ... announced the completion of its corporate rebranding efforts, ... of its flagship website. The rebranding ... over the past decade and enables Intelsius to ...
... OXFORD, England and LANGHORNE, Pennsylvania, September 1, 2010, ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in ...
Cached Biology Technology:Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility 2Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility 3DGP Group Rebrands as Intelsius and Announces Launch of New, Innovative Packaging System - Orcathermâ„¢ 2EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 2EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 3EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 4EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 5EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 6EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 7
(Date:8/27/2014)... Aug. 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... sold in the offering consists of 2,000 shares of ...
(Date:8/27/2014)... megafauna mastodons, short-faced bears, giant ground sloths, saber-toothed ... to 13,000 years ago at the end of the ... long been debated by scientists who, until recently, could ... scientists, including UC Santa Barbara,s James Kennett, professor emeritus ... comet collision with Earth played a major role in ...
(Date:8/27/2014)... the human genome was unveiled today in the form ... yet of how the genomes of the fruit fly, ... August 28 in in the journal Nature , ... genomes is "read out," and how their DNA and ... billions of entries to a publicly available archive of ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Nanodiamonds are forever 2Nanodiamonds are forever 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
... has announced the winner of its Minority Affairs Committee ... Meeting at the Moscone Center in San Francisco, February ... at the Biophysical Society Annual Meeting by minority students ... be honored at a reception on Saturday, February 15. ...
... 2014 FASEB Science Research Conference on Nutrient Sensing ... the mechanisms by which nutrients and metabolites transduce ... genomics, epigenetics, metabolomics and the micro biome, in ... fueling development of new diagnostics, therapeutics, and personalized ...
... MD This 2014 FASEB Science Research Conference focuses ... our understanding of the progression of events that are ... replication, assembly, and exit. Virus assembly includes the process ... that purpose. Knowledge on virus structure and ...
Cached Biology News:Biophysical Society announces winners of 2014 Minority Affairs Committee Travel Awards 2
... in Tris buffer, pH 10.2 give activity ... system. Assays in diethanolamine buffer, pH 9.8 ... glycine buffer system. Protein determined by Biuret ... salts Preparation Unit Definition: One unit will ...
... traps a wide variety of solvent vapors that can ... flask (GCF400) allows for the collection of liquid into ... time minimizes waiting period., Ultra low -104 ... , Digital Display of ...
... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...
Thermo Forma provides an array of accessory Racks for the Cryo/CryoPlus 16" Diameter storage system. To maximise inventory capacity a Jumbo Arrowhead configuration is recommended. You may choose betw...
Biology Products: